Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
The purpose of this study is to evaluate the efficacy and safety of new oral anticoagulants and vitamin K antagonists for the anticoagulation for the implantation of vena cava filters in patients with deep venous thrombosis.
Official title: An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2020-05-08
Completion Date
2024-10-01
Last Updated
2024-04-18
Healthy Volunteers
No
Conditions
Interventions
Rivaroxaban
15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
Warfarin
3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
Nadroparin
Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
Locations (7)
Anhui Provincial Hospital
Hefei, Anhui, China
Yantai Yuhuangding Hospital
Yantai, Shangdong, China
Huadong Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Shanghai 5th People's Hospital
Shanghai, Shanghai Municipality, China
Zhongshan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
The second affiliated hospital of zhejiang university school of medicine
Hangzhou, Zhejiang, China